Structure Therapeutics' upside potential

What happened: Deep Track Capital acquired 168,066 shares of Structure Therapeutics in Q1 2023, investing approximately $11.5 million. Meanwhile, ACT Capital Management fully exited its $2.6 million position in the same period. Analysts maintain a strongly bullish consensus on GPCR, with a median 1-year target price of $107.77.

Market impact: The biotech sector is affected, with Structure Therapeutics' stock price reacting to these institutional moves. The company's upside potential is under scrutiny, given the mixed signals from these fund activities. The overall biotech sentiment remains positive, supported by broad analyst optimism.

What to watch next: Upcoming catalysts include Structure Therapeutics' Q2 2023 earnings release (scheduled for late July) and any regulatory updates on the company's pipeline. Additionally, monitor further institutional activity, as it may indicate a shift in investor sentiment towards GPCR.